NMTR
Income statement / Annual
Last year (2022), 9 Meters Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, 9 Meters Biopharma, Inc.'s net income was -$45.52 M.
See 9 Meters Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.88 M |
$4.07 M |
$8.27 M |
$11.34 M |
$3.44 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.95 M
|
$3.33 M
|
$7.84 M
|
$11.11 M
|
$2.84 M
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$64.00 K
|
$736.00 K
|
$426.00 K
|
$234.00 K
|
$606.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
-0.03
|
0.18
|
0.05
|
0.02
|
0.18
|
| Research and Development Expenses |
$31.01 M
|
$22.00 M
|
$10.93 M
|
$13.72 M
|
$7.56 M
|
$190.00 K
|
$270.00 K
|
$333.00 K
|
$542.00 K
|
$709.00 K
|
| General & Administrative Expenses |
$11.01 M
|
$9.66 M
|
$10.52 M
|
$10.57 M
|
$10.67 M
|
$4.98 M
|
$3.98 M
|
$3.63 M
|
$2.65 M
|
$1.75 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.43 M
|
$2.43 M
|
$2.93 M
|
$3.72 M
|
$1.52 M
|
| Selling, General & Administrative Expenses |
$11.01 M
|
$9.66 M
|
$10.52 M
|
$10.57 M
|
$10.67 M
|
$6.41 M
|
$6.41 M
|
$6.55 M
|
$6.37 M
|
$3.26 M
|
| Other Expenses |
$0.00
|
$0.00
|
$39.42 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$42.02 M
|
$31.66 M
|
$60.88 B
|
$24.28 M
|
$18.22 M
|
$6.60 M
|
$6.68 M
|
$6.89 M
|
$6.91 M
|
$3.97 M
|
| Cost And Expenses |
$42.02 M
|
$31.66 M
|
$21.45 M
|
$24.28 M
|
$18.22 M
|
$8.55 M
|
$10.01 M
|
$14.73 M
|
$18.02 M
|
$6.81 M
|
| Interest Income |
$501.23 K
|
$22.71 K
|
$18.99 K
|
$185.27 K
|
$163.83 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$2.67 M
|
$47.19 K
|
$4.05 M
|
$1.83 M
|
$6.15 M
|
$93.00 K
|
$825.00 K
|
$1.38 M
|
$1.66 M
|
$66.00 K
|
| Depreciation & Amortization |
$8.52 K
|
$5.13 M
|
$39.46 M
|
$1.47 M
|
$19.56 K
|
$131.00 K
|
$131.00 K
|
$54.00 K
|
-$2.47 M
|
$0.00
|
| EBITDA |
-$41.09 M |
-$31.63 M |
-$21.42 M |
-$24.08 M |
-$18.04 M |
-$5.62 M |
-$5.81 M |
-$7.30 M |
-$9.38 M |
-$3.37 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-2.98
|
-1.43
|
-0.88
|
-0.83
|
-0.98
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-4.72
|
-1.64
|
-0.83
|
-0.61
|
-1.15
|
| Total Other Income/Expenses Net |
-$1.75 M
|
-$17.48 K
|
-$36.02 M
|
-$1.13 M
|
-$5.94 M
|
$963.00 K
|
$468.00 K
|
-$1.85 M
|
-$4.13 M
|
$540.00 K
|
| Income Before Tax |
-$43.77 M
|
-$36.78 M
|
-$61.50 M
|
-$27.05 M
|
-$24.16 M
|
-$7.93 M
|
-$6.21 M
|
-$8.74 M
|
-$11.04 M
|
-$3.43 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-4.21
|
-1.53
|
-1.06
|
-0.97
|
-1
|
| Income Tax Expense |
$1.75 M
|
$47.19 K
|
$4.05 M
|
$1.83 M
|
$213.83 K
|
$0.00
|
$2.00 K
|
$2.00 K
|
$13.00 K
|
$4.00 K
|
| Net Income |
-$45.52 M
|
-$36.83 M
|
-$65.54 M
|
-$28.87 M
|
-$24.16 M
|
-$7.93 M
|
-$6.21 M
|
-$8.74 M
|
-$11.06 M
|
-$3.44 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-4.21
|
-1.53
|
-1.06
|
-0.97
|
-1
|
| EPS |
-3.51 |
-3.03 |
-12.41 |
-17.33 |
-19.52 |
-13.33 |
-225.11 |
-330.66 |
-416.15 |
-129.94 |
| EPS Diluted |
-3.51 |
-3.03 |
-11.6 |
-16.2 |
-19.6 |
-13.33 |
-225.11 |
-328.98 |
-416.15 |
-129.28 |
| Weighted Average Shares Out |
$12.96 M
|
$12.16 M
|
$5.28 M
|
$1.67 M
|
$1.24 M
|
$594.41 K
|
$27.60 K
|
$26.44 K
|
$26.57 K
|
$26.44 K
|
| Weighted Average Shares Out Diluted |
$12.96 M
|
$12.16 M
|
$5.28 M
|
$1.67 M
|
$1.24 M
|
$594.41 K
|
$27.60 K
|
$26.57 K
|
$26.57 K
|
$26.57 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
